Delmar Pharma (DMPI) presented clinical updates from the Company’s ongoing first- and second-line trials in patients with MGMT-unmethylated GBM at ASCO
Tweet Send to a Friend
Delmar Pharma (NASDAQ: DMPI) disclosed in an SEC filing:Item 8.01. Other Events. On May 31, 2019, DelMar Pharmaceuticals, Inc. (“DelMar” ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
